MS imaging Analysis to identify protein expressions regulating malignant transformation in glioma
Project/Area Number |
25670623
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Neurosurgery
|
Research Institution | Kyoto University |
Principal Investigator |
SUSUMU Miyamoto 京都大学, 医学(系)研究科(研究院), 教授 (70239440)
|
Co-Investigator(Kenkyū-buntansha) |
ARAKAWA Yoshiki 京都大学, 大学院医学研究科, 助教 (20378649)
|
Co-Investigator(Renkei-kenkyūsha) |
FUMIHIKO Matsuda 京都大学, 大学院医学研究科, 教授 (50212220)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 神経膠腫 / 悪性転化 / MSイメージング / 質量分析 / グリオーマ / 質量分析解析 / 質量顕微鏡 / mass spectrometry / エピジェネティック |
Outline of Final Research Achievements |
The aim of the research project is to screen protein expressions associated with malignant transformation in glioma, to identify the driver proteins, and to reveal the novel mechanism. We evaluated the pretreatment conditions for MS imaging and visualized the protein expressions of clinical samples. To identify the proteins detected by MS imaging, the pretreatment conditions for LC/MS/MS analysis was examined. As preliminary results, we identified some proteins which has been known to be involved in gliomagenesis.
|
Report
(3 results)
Research Products
(4 results)
-
-
[Journal Article] Retrospective Analysis of Bevacizumab in Combination With Ifosfamide, Carboplatin, and Etoposide in Patients With Second Recurrence of Glioblastoma2013
Author(s)
oshiki Arakawa, Takashi Mizowaki, Daiki Murata, Koichi Fujimoto, Takayuki Kikuchi, Takeharu Kunieda, Jun C. Takahashi, Yasushi Takagi, Susumu Miyamoto.
-
Journal Title
Neurologia medico-chirurgica
Volume: 53
Issue: 11
Pages: 779-785
DOI
NAID
ISSN
0470-8105, 1349-8029
Related Report
Peer Reviewed
-
-